中国基层医药
中國基層醫藥
중국기층의약
CHINESE JOURNAL OF PRIMARY MEDICINE AND PHARMACY
2014年
11期
1682-1684
,共3页
心力衰竭,充血性%血管紧张素转换酶抑制药%β受体阻滞剂%基质金属蛋白酶类
心力衰竭,充血性%血管緊張素轉換酶抑製藥%β受體阻滯劑%基質金屬蛋白酶類
심력쇠갈,충혈성%혈관긴장소전환매억제약%β수체조체제%기질금속단백매류
Heart failure,congestive%Angiotensin-converting enzyme inhibitors%Beta-blocker%Matrix metalloproteinases
目的 观察卡托普利联合美托洛尔对慢性心力衰竭(CHF)的治疗作用,并探讨其作用机制.方法 60例CHF患者分为常规治疗组(A组)和卡托普利+美托洛尔治疗组(B组),观察治疗后左心室射血分数(LVEF)、左室舒张末期内径(LVEDD)、基质金属蛋白酶-9(MMP-9)和高敏C反应蛋白(hs-CRP)水平变化.酶联免疫吸附双抗体夹心法(ELISA)检测血清MMP-9表达水平;乳胶增强免疫比浊法检测血清hs-CRP表达水平.结果 B组LVEF及LVEDD[(63.21±6.09)％、(58.42±5.73) mm]的改善显著优于A组[(41.13±3.67)％、(66.24±4.24) mm](t=7.62、6.54,均P＜0.01);B组MMP-9和hs-CRP[(1.31±0.24) ng/mL、(6.34±0.58) mg/L]水平显著低于A组[(2.23±0.39) ng/mL、(8.31±0.74) mg/L](t=6.82、7.03,均P＜0.01).A和B组的有效率分别为36.7％和73.3％,差异有统计学意义(x2=6.90,P＜0.05).结论 卡托普利与美托洛尔联合治疗对CHF患者心功能具有保护作用,抑制MMP-9和hs-CRP的表达可能是其主要的作用机制.
目的 觀察卡託普利聯閤美託洛爾對慢性心力衰竭(CHF)的治療作用,併探討其作用機製.方法 60例CHF患者分為常規治療組(A組)和卡託普利+美託洛爾治療組(B組),觀察治療後左心室射血分數(LVEF)、左室舒張末期內徑(LVEDD)、基質金屬蛋白酶-9(MMP-9)和高敏C反應蛋白(hs-CRP)水平變化.酶聯免疫吸附雙抗體夾心法(ELISA)檢測血清MMP-9錶達水平;乳膠增彊免疫比濁法檢測血清hs-CRP錶達水平.結果 B組LVEF及LVEDD[(63.21±6.09)％、(58.42±5.73) mm]的改善顯著優于A組[(41.13±3.67)％、(66.24±4.24) mm](t=7.62、6.54,均P＜0.01);B組MMP-9和hs-CRP[(1.31±0.24) ng/mL、(6.34±0.58) mg/L]水平顯著低于A組[(2.23±0.39) ng/mL、(8.31±0.74) mg/L](t=6.82、7.03,均P＜0.01).A和B組的有效率分彆為36.7％和73.3％,差異有統計學意義(x2=6.90,P＜0.05).結論 卡託普利與美託洛爾聯閤治療對CHF患者心功能具有保護作用,抑製MMP-9和hs-CRP的錶達可能是其主要的作用機製.
목적 관찰잡탁보리연합미탁락이대만성심력쇠갈(CHF)적치료작용,병탐토기작용궤제.방법 60례CHF환자분위상규치료조(A조)화잡탁보리+미탁락이치료조(B조),관찰치료후좌심실사혈분수(LVEF)、좌실서장말기내경(LVEDD)、기질금속단백매-9(MMP-9)화고민C반응단백(hs-CRP)수평변화.매련면역흡부쌍항체협심법(ELISA)검측혈청MMP-9표체수평;유효증강면역비탁법검측혈청hs-CRP표체수평.결과 B조LVEF급LVEDD[(63.21±6.09)％、(58.42±5.73) mm]적개선현저우우A조[(41.13±3.67)％、(66.24±4.24) mm](t=7.62、6.54,균P＜0.01);B조MMP-9화hs-CRP[(1.31±0.24) ng/mL、(6.34±0.58) mg/L]수평현저저우A조[(2.23±0.39) ng/mL、(8.31±0.74) mg/L](t=6.82、7.03,균P＜0.01).A화B조적유효솔분별위36.7％화73.3％,차이유통계학의의(x2=6.90,P＜0.05).결론 잡탁보리여미탁락이연합치료대CHF환자심공능구유보호작용,억제MMP-9화hs-CRP적표체가능시기주요적작용궤제.
Objective To investigate the effects of ACEI combined with beta-blocker on cardiac function in patients with chronic heart failure (CHF)and explore its action mechanisms.Methods 60 CHF patients were enrolled in this study.The patients were randomly divided into the two groups:conventional treatment group(group A,n =30),ACEI combined with beta-blocker treatment group (group B,n =30).The LVEF,LVEDD,MMP-9,and hsCRP were recorded after treatment.The expression of MMP-9 was measured by ELISA.The level of serum hs-CRP was measured by latex enhanced immunoturbidimetric assay.Results The improvement of LVEF and LVEDD in B group [(63.21 ± 6.09) ％,(58.42 ± 5.73)mm] were better than those in A group [(41.13 ± 3.67) ％,(66.24 ± 4.24) mm] (t =7.62,6.54,P ＜ 0.01).The expressions of MMP-9 and hs-CRP in group B [(1.31 ± 0.24) ng/ml,(6.34 ± 0.58) mg/L] were significantly lower than those in A group[(2.23 ±0.39) ng/mL,(8.31 ±0.74) mg/L] (t =6.82,7.03,P ＜0.01).The total effective rate in A group was 36.7％,which was significantly lower than 73.3％ in B group(x2 =6.90,P ＜ 0.05).Conclusion The cardiac function was improved by ACEI combined with beta-blocker treatment in CHF patients.The downregulation of MMP-9 and hs-CRP may play a key role in the effective ACEI combined with beta-blocker treatment.
